Trends for in-office usage of pharmacological sedation agents in India: A narrative review

Sakshi Joshi, Anil Gupta, Shalini Garg, Shikha Dogra
Department of Pediatric and Preventive Dentistry, SGT University, Gurugram, Haryana, India

Abstract

Background and Aims: Conscious sedation plays a significant role in in-office pharmacological behavior management for short-term procedures in children and apprehensive adults. The advantage conscious sedation provides is by improving quality of care provided by decreasing pain and anxiety while maintaining a patent airway and adequate spontaneous ventilation.

Methodology: Present review was conducted to evaluate recent trends regarding use of in-office pharmacological sedation agents in India. A rigorous search was conducted through five electronic databases namely PubMed, Scopus, Web of Science, Cochrane Database, and CTRI (Clinical Trial Registry – India). The search period was defined to be last 5 years, that is, from 1st January 2014 to 31st July 2019. Terminologies “Conscious Sedation,” “In-office Sedation,” “Midazolam,” “Nitrous Oxide,” “India” were included in the search. The Boolean Operation “OR” and “AND” were applied to combine the terminologies.

Results: A total of 20 studies were identified following strict inclusion and exclusion criteria. The included studies were evaluated for study design, specialty involved, number of individuals and their age groups, drugs compared along with route and dosage, procedures undertaken, place of study and results. Dental fraternity (13) had more number of trials conducted as compared to medical fraternity (7) in the stimulated period, with South Indian region having maximum trials registered or published.

Conclusion: Midazolam was observed to the drug of choice for in-office sedation procedures in Indian Scenario. The limitation of study is that the published clinical studies are limited to a few states of India.

Keywords: Conscious sedation, India, Midazolam

Introduction

Conscious Sedation (Moderate Sedation/Analgesia) is a drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by a little tactile stimulation.[1]

Since the introduction of nitrous oxide by Humphry Davy in 1789, sedative agents had become an imperative part of medical community.[2] Since then in a quest to find the best sedative many agents have been introduced. This included familiarization of chloral hydrate in 1870s,[3] midazolam in 1983, flumazenil in 1988, and propofol in 1990s[4] and in 1999 came dexmedetomidine as an approved agent for short-term sedative procedures (>24 h).[5]

Although the term conscious sedation was coined in 1985 to describe dental patients who were lightly sedated, but its use soon spread across areas of medical practice. It was in 1996 that the ASA Taskforce replaced it with a more precise term “sedation-analgesia,” but the term “conscious sedation” continues to be widely used.[6]

In recent years, the healthcare world has seen a shift in preference for conscious sedation over general anesthesia. It
can be contributed to the decreased risks of morbidity and mortality as compared to general anesthesia. Also, the delirium associated with general anesthesia is not an issue under conscious sedation. However, the essential non feeding period has to be followed before undergoing general anesthesia or conscious sedation. Although, the time duration differs.

Another advantage conscious sedation provides is by reducing anxiety, not just limited to children but extending to adults too. Aiding in its widespread popularity in the western world, wherein UK (2009) the rate of usage of sedation for pediatric patients was 90% irrespective of the dentist specialization. Justifying the widespread usage of sedation in dentistry, National Commission on Recognition of Dental Specialties and Certifying Boards recognized Dental anesthesiology as 10th dental specialty on the basis of a resolution from the American Society of Dentist Anesthesiologists to recognize it as a separate dental specialty. However, observing the scenario in India is tough because of the scarcity of data available with regards to specialist preference of sedative agents. Also, trials registered are less or incomplete till date. Further in this review, midazolam and nitrous oxide were taken as the gold standard drugs given to their popularity in the literature. Hence, this review has been carried out to observe the trend of change occurring in the field of in-office sedation in India.

Methodology

The present review was carried out using the framework provided by Arksey H (2005) and Levac D (2010). A rigorous search was carried out using five electronic databases: PubMed, Scopus, Web of Science, Cochrane Database, and CTRI (Clinical Trial Registry – India). The search period was defined to include literature for the last 5 years, that is, from 1st January 2014 to 31st July 2019. Terminologies “Conscious Sedation,” “In-Office Sedation,” “Midazolam,” “Nitrous Oxide,” “India” was included in the search. The Boolean operation “OR” and “AND” were applied to combine the terminologies.

The title and abstract of the searched articles were evaluated by the main author, to identify the studies that met with the inclusion criteria of the review. Observational studies (case-control, cross-sectional, cohort), experimental (both randomized or non-randomized clinical trials), which either used nitrous oxide or midazolam alone or in combination with other sedative agents, whose text was available in the English language, which were published between 2014 and July 2019 and were conducted in India were included in the review. Systemic reviews, case reports, guidelines, and incomplete registered trials were excluded. Studies were included irrespective of age groups, healthcare specialty, or their association with any specific medical or dental health procedures. After the initial screening, a manual search was executed in the reference list of included studies. Studies that were accessible through more than one database were considered only once.

Data from the included studies was extracted and assembled in a table form under various headings: study details (author(s), year of publication and state where the study was conducted), participants (number and age group), methodology (department where the study was conducted, study design, procedure performed and time duration), agents compared (agents along with route and its dosage) and results [Table 1]. If any clarification was required, it was sought out either directly by contacting the corresponding author (through email) or indirectly through the editor of the journal.

Results

Study selection

The search was conducted using various databases (PubMed, Scopus, Web of Science, Cochrane Database, and CTRI), which resulted in the identification of 4,607 articles. After the removal of duplicates, 4,000 records remained. The articles not related to the topic of this review were excluded via screening of title and abstract and the literature came down to 2,000. Adding the time constrain (2014–2019), the number of included literature reduced to 500. Further on reviews, meta-analysis, editorials, letter to editors, questionnaire studies, case reports, and incomplete registered trials whose results were unknown were excluded bringing down the included literature number to 18. Two studies were further included after manual searching of the reference list. Therefore, a total of 20 studies were found to be fulfilling the criteria and were included in this review [Figure 1].

Study characteristics

The characteristics of the included studies are mentioned in Table 1. From the 20 studies included, 19 were randomized trial and 1 was a cross-sectional study. Based on blinding done in the Trial: double, triple and partial blinding was identified and was reported in 7, 1, and 1 trial, respectively, and no blinding was performed in 10 trials. All of the trials were prospective in conduct.

In the present review, an observation regarding the specialty conducting the trial was made. Out of total of 20 trials, 7 were conducted by medical fraternity with pediatric, otolaryngology, and pulmonary medicine department taking credit for 1 trial.
### Table 1: Characteristics of Studies Included

| Author (Year) | Control drug | Agent compared andDuration | Speciality (Type of procedure & Duration) | State where Trial was conducted | Results |
|---------------|--------------|---------------------------|------------------------------------------|-------------------------------|---------|
| Dhuvad J.M et al. (2014) [13] | Midazolam (Intravenous 1.5 mg/kg) | Propofol (Intravenous 20 μg/kg/min) | Oral and Maxillofacial Surgery (3rd Molar Extraction, 20 mins) | Maharashtra | Recovery rate was faster in propofol group (within 2 hrs) as compared to midazolam group. Side effects were least in propofol group. Patient satisfaction was higher in propofol group (96.66%) as compared to midazolam group (60%). |
| Mitra S et al. (2014) [14] | Midazolam (Intranasal 0.3 mg/kg) | Clonidine (Intravenous 4 μg/kg) | Anaesthesiology (minor elective surgical procedures such as hydrocele repair, herniorrhaphy, circumcision or eye surgery, 25 mins) | Chandigarh | Midazolam group had faster onset (P<0.05) compared to Clonidine whereas Clonidine has better drug acceptance (P<0.001). |
| Surender MN et al. (2014) [15] | Midazolam (0.2 mg/kg) (Intranasal) | Ketamine (Intranasal 5 mg/kg), Dexmedetomidine (2 diff dosages) (Intranasal D1 1 μg/kg and D2 1.5 μg/kg) | Pediatric and Preventive Dentistry (Early Childhood Caries treatment: extraction, restoration, pulp therapy, 30-45 mins) | Uttar Pradesh | The onset of sedation was significantly faster in midazolam and ketamine group as compared to both dexmedetomidine groups (P<0.001). Success rate was highest in D1 (85.7%) followed by D2 (81%), K1 (66.7%) and M1 (61.9%). However difference was not statistically significant (P>0.05). Pain during injection experienced in propofol group was statistically significant than in midazolam group (P<0.001). The onset of action was significantly earlier in propofol group than in midazolam group (P<0.001). Significant difference was observed in the level of discomfort experienced by children between both the groups (P<0.01). Statistically significant difference in the behaviour of children during and after the procedure in both treatment groups (P<0.01). |
| Keerthy PH et al. (2015) [16] | Midazolam (Intravenous 75 μg/kg) | Propofol (Intravenous Induction 0.5 mg/kg and maintenance 50 μg/kg/min) | Oral and Maxillofacial Surgery (Disimpaction of Mand. 3rd Molar, 25 mins) | Karnataka | Pain during injection experienced in propofol group was statistically significant than in midazolam group (P<0.001). The onset of action was significantly earlier in propofol group than in midazolam group (P<0.001). Significant difference was observed in the level of discomfort experienced by children between both the groups (P<0.01). Statistically significant difference in the behaviour of children during and after the procedure in both treatment groups (P<0.01). |
| Takkar D et al. (2015) [17] | Nitrous Oxide + Oxygen (Inhalation 40%-60%) | Oxygen (Inhalation 100%) | Pediatric and Preventive Dentistry (Inferior alveolar block administration, 5 mins) | Karnataka | Significant improvement in movement and crying scores was observed after administration of drug (P<0.001). Overall behaviour at end of treatment was also significantly improved after sedation (P<0.001). Onset of sedation was 6.11 min faster in aerosol as compared to oral midazolam. |
| Chopra R et al. (2015) [18] | Midazolam (Intranasal 0.3 mg/kg) | Midazolam (Aerosol 0.3 mg/kg) | Pediatric and Preventive Dentistry (treatment requiring local anaesthesia: extraction, restoration, pulp therapy, 26.7±12.2 min) | Haryana | |

Contd...
Table 1: Contd...

| Author (Year) | Nature of Trial | No of Individuals (Age Group) | Control drug (Route and dosage) | Agent compared (route and dosage) | Speciality (Type of procedure & Duration) | State where Trial was conducted | Results |
|---------------|-----------------|-------------------------------|---------------------------------|-----------------------------------|------------------------------------------|------------------------------|---------|
| Musani IE et al. (2015) [20] | Randomized, cross-over study | 30 (4-10 yrs) | Midazolam (Oral 0.2 mg/kg) and Nitrous Oxide - Oxygen (Inhalation 40%-60%) | Propofol (108 Mins) | Pediatric and Preventive Dentistry (Extraction, Indirect Pulp Capping, Pulpotomy, Pulpectomy; 20-30 Mins) | Maharashtra | The onset of sedation was significantly faster in intranasal group :12.1 min as compared to oral group 20.1 min (P<0.001). The alertness was statistically higher in intranasal group as compared to oral group (P<0.05). Recovery was faster in intranasal group. |
| Stephen MC et al. (2015) [21] | Prospective, randomized, double blind, placebo controlled study | 82 (1-6 yrs) | Midazolam (Intranasal 0.5 mg/Kg) | Chloral Hydrate (Oral 50 Mg/Kg) | Otolaryngology, speech and hearing (auditory brainstem response testing, 60-90 mins) | Tamil Nadu | Chloral Hydrate showed earlier onset of sedation (66%) as compared to Midazolam (33%). Recovery was faster in Chloral Hydrate group (78 Mins) as compared to Midazolam (108 Mins) (P<0.05) |
| Thota RS (2015) [22] | Randomised trial | 40 (18-75 yrs) | Fentanyl (Intravenous 1.5 μg/Kg) and Midazolam (Intravenous 0.03 mg/Kg) | Fentanyl (Intravenous 1.5 μg/kg) and Propofol (Intravenous 0.75 mg/kg) | Anaesthesiology (Tympanoplasty, 30-60 mins) | Maharashtra | Fentanyl and Propofol group showed faster recovery and less nausea and vomiting. |
| Done V et al. (2016) [23] | Randomized, Factorial Design study | 30 (3-9 yrs) | Midazolam (Oral 0.5 mg/kg) and Nitrous Oxide - Oxygen (Inhalation 70%-30%) | Oral Ketamine (Oral 5 mg/kg) and Nitrous Oxide - Oxygen (Inhalation 70%-30%) | Pediatric and Preventive Dentistry (Primary teeth Extraction, 15 mins) | Andhra Pradesh | No significant difference (P>0.05) on comparison of effectiveness of Oral Midazolam-N₂O with Oral Ketamine-N₂O when physiological parameters were taken into consideration. Psychomotor performance was found to be marginally better with Oral Midazolam-N₂O compared to Oral Ketamine-N₂O. |
| Shanmugaavel A.K. et al. (2016) [24] | Randomized controlled trial | 40 (3-5 yrs) | Midazolam (Intranasal 0.2 mg/kg) | Midazolam (Sublingual 0.2 mg/kg) | Pediatric and Preventive Dentistry (Extraction, Indirect Pulp Capping, Pulpotomy, Pulpectomy; 20-30 Mins) | Tamil Nadu | Sublingual route was preferred significantly as compared to intranasal route (P=0.001). Significantly reduced anxiety score was observed in both intranasal and sublingual groups (P<0.001) over time. |
| Malhotra RU et al. (2016) [25] | Prospective, randomized, double blind study | 36 (3-9 yrs) | Midazolam (Oral 0.5 mg/kg) and Ketamine (Oral 5 mg/kg) | Dexmedetomidine (Intranasal 1 μg/kg) | Pediatric and Preventive Dentistry (Early Childhood Caries t-1 (extraction, restoration, pulp therapy, 30-45 mins)) | Himachal Pradesh | Hemodynamic changes were statistically insignificant in both groups. About 75% patients receiving Midazolam + Ketamine were successfully sedated as compared to 53.9% receiving Dexmedetomidine. |
| Bishnoi V et al. (2016) [26] | Randomized, parallel group study | 52 (18-50 yrs) | Fentanyl And Midazolam (Intravenous Fentanyl - 0.5 Mg/ Kg And Midazolam - 0.03 mg/kg for 10 mins followed by continuous infusion of 0.5 to 1.16 μg/kg/h and 0.03-0.07 mg/kg/h) | Dexmedetomidine (Intravenous 1 μg/kg over 10 mins followed by continuous infusion 0.03-0.7 μg/kg/h) | Anaesthesia and intensive care (burr hole surgery for chronic subdural hematoma, 60 mins) | Haryana | Dexmedetomidine group showed faster postoperative recovery (P=0.00). Surgeon satisfaction was better in dexmedetomidine group compared to midazolam and fentanyl group (P=0.007). |

Contd...
Table 1: Contd...

| Author (Year)                    | No of Individuals (Age Group) | Control drug (Route and dosage) | Agent compared (route and dosage) | Speciality (Type of procedure & Duration) | State where Trial was conducted | Results                                                                 |
|--------------------------------|-------------------------------|---------------------------------|----------------------------------|-------------------------------------------|-------------------------------|------------------------------------------------------------------------|
| Ramaswamy SS et al. (2016)      | 60 (50-70 yrs)                | Fentanyl (Intravenous 12.5 μg/kg) and Midazolam (Intravenous 0.02 mg/kg) | Dexmedetomidine (intravenous 2 doses 0.5 μg/kg and 0.25 μg/kg for 10 mins, followed by titrated maintenance dose of 0.25-0.4 μg/kg/h) | Anaesthesiology (Vitreoretinal surgery, 60 mins) | Karnataka                     | Dexmedetomidine (0.5 μg/kg) group had statistically significant bradycardia (P<0.001), hypotension (P=0.008). Midazolam-Fentanyl group had significantly higher incidence of nausea (P=0.001) and vomiting (P=0.002) |
| Subramaniam P et al. (2017)     | 60 (5-10 yrs)                 | Nitrous Oxide-Oxygen (Inhalation 40%-60%) | Triclofos Sodium (Oral 70 mg/kg) | Pediatric and Preventive Dentistry (Extraction, restorations and endodontic treatment, 30-45 mins) | Karnataka                     | Patient acceptance was statistically significant for Triclofos Sodium as compared to N₂O (P=0.002). Children sedated with Triclofos sodium were significantly more sleepy and disoriented as compared to N₂O (P=0.005). Time taken to achieve minimal sedation was less in rapid induction group as compared to slow induction (P<0.001). No statistically significant difference was found in incidence of hypoxia in both groups (P<0.512) |
| Samir PV et al. (2017)          | 60 (5-12 yrs)                 | Nitrous Oxide-Oxygen (Slow Induction Technique 30%-70%) | Nitrous Oxide-Oxygen (Preadjusted mix + Rapid Induction Technique 30%-70%) | Pediatric and Preventive Dentistry (Pulp Therapy, 45 mins) | Telangana                     | Patient satisfaction was highest in Fentanyl and Midazolam group followed by Midazolam and placebo group (P<0.001). Physician feasibility was also higher in Fentanyl and Midazolam group (P = 0.004) |
| Prabhudev AM et al. (2017)      | 144 (30-65 yrs)               | Midazolam (Intravenous 0.035 mg/kg) | Fentanyl (Intravenous 50 μg/ml) and Midazolam (Intravenous 0.035 mg/kg) | Pulmonary Medicine (Bronchoscopy, 30-60 mins) | Karnataka                     | Mean time to sedation and recovery was shorter in Propofol group (P<0.001) and mean depth of sedation was greater in Ketamine and Midazolam group (P<0.001). Preoperative to postoperative anxiety scores have decreased significantly within both groups but there was no statistically significant difference in pre and post-operative anxiety scores between the groups. |  
| Chayapathi V et al. (2018)      | 152 (1-12 yrs)                | Ketamine (Intravenous 2 mg/kg) and Midazolam (Intravenous 0.2 mg/kg) | Propofol (Intravenous 2.5 mg/kg) | Pediatrics (Intrathecal chemotherapy, 30 mins) | Delhi                         |  
| Kunusoth R et al. (2019)        | 60 (10-50 yrs)                | Midazolam (Intravenous 0.1 mg/kg) | Midazolam (Intranasal 0.1 mg/kg) | Oral and Maxillofacial Surgery (Minor Oral Surgery, 15-60 mins) | Telangana                     |  
| Sivasubramini S.M. et al. (2019) | 60 (18-40 yrs)               | Midazolam (Intravenous 0.05 mg/kg) | Dexmedetomidine (Intravenous 1 μg/kg for 10 mins additional dosage 0.5 μg/h) | Oral and Maxillofacial Surgery (bite force during minor oral surgery, 30 mins) | Tamil Nadu                    | Dexamethasone group had statistically significant sedation score as compared to midazolam (P<0.05). Bite force increased administration of either drugs (no significant result (P>0.05) |

Each and rest 4 being conducted by anesthesiology department. And dental specialty was credited for the conductance of 13 trials (9 were concerned with Pediatric and Preventive Dentistry and 4 with Oral and Maxillofacial Surgery Departments). However, observing the preference of conscious sedation for in-office procedures between dental and medical specialty, the difference was not statistically significant using Fisher’s exact test (P = 0.344).

Observing the preference of agents used in the medical and dental setting as a conscious sedative agent for in-office procedures over the 5 years (2014–2019). Maximum studies
throughout the period have been conducted in 2016 for both medical and dental specialty. For medical in-office procedures midazolam alone remained a constant drug of choice from 2014 to 2017 and no trials reported for 2018 and 2019 [Graph 1].

Discussing the agents usage in procedures of different durations. For this parameter, the studies were divided into two groups—procedures requiring less than 30 min (<30 min) and more than 30 min (>30 min). The midazolam appeared to be the most used agent in procedures requiring <30 min (8) and >30 min (8), followed by dexmedetomidine and fentanyl both used in five times each for procedures requiring more than 30 min [Graph 2]. Based on the agent used in the trial midazolam was chosen as an agent in 15 trials (irrespective of the route) and nitrous oxide was used in 3 trials and 2 trials used combination of both. As comparative agents, Propofol was used in 4 trials, Ketamine in 4 trials, Dexmedetomidine in 5 trials, Clonidine in 1 trial, Triclofos Sodium in 1 trial, and Chloral Hydrate in 1 trial. Seven trials were those which used midazolam as an agent in combination with other drugs [Graph 1]. Midazolam had been administered 20 times in 17 studies, in varying concentrations (0.035 mg/kg, 0.03 mg/kg, 0.075 mg/kg, 0.05 mg/kg, 0.005 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, and 0.5 mg/kg). The route of administration of midazolam was observed to be intravenous route (9 trials) followed by intranasal (6 trials), oral (4 trials), sublingual (1 trial), and buccal aerosol (1 trial), wherein 3 trials comparison between different routes was done. Propofol was used in concentration of 0.02 mg/kg, 0.5, 1, 0.75, and 2.5 mg/kg. Dexmedetomidine concentration used was 0.5–1.5 μg/kg. Ketamine concentration used was 2 mg/kg (1 study) and 5 mg/kg (3 studies). Clonidine concentration was 4 μg/kg intranasally, Triclofos Sodium in 70 mg/kg in oral form and Chloral Hydrate 50 mg/kg in oral form. The number of participants included in the selected trials ranged from 30 to 144. According to the age group involved, studies were characterized into 2 groups: Group 1- included studies where the age group was less than 16 years and Group 2 – where the age group was above 16 years of age. 12 studies were characterized under Group 1, with 7 studies under Group 2, and 1 study fell under both the groups.

Observing the distribution of trials throughout the Indian territory. South India dominated this distribution with 11 trials conducted within its region, with maximum trials been conducted in Karnataka (5) followed by the Northern region with 6 and 3 trials in Western India. While Central and Eastern India reportedly had no trials. All trials in the Western region were conducted in Maharashtra state (3) [Figure 2].

Discussion

Among the two pharmacological behavior management techniques, conscious sedation preference has increased over time compared to general anesthesia for procedures involving both dental and medical fraternity. The reason for this is the decline in the mortality risk and delirium, along with the improved recovery time and reduced reliance on anesthetic staff as it can be performed even without the presence of anesthesiologist.\textsuperscript{33,34}

The primary goal for conscious sedation is to minimize or eliminate pain and anxiety during treatment.\textsuperscript{35} While
maintaining a patent airway without assistance and cardiovascular function, adequate ventilation, and responses to the verbal communication.\[36\] This stage can be achieved via a range of drugs with different routes of administration (inhalation, oral, intravenous, intramuscular, rectal) and varying dosages.\[13-32,37\] Among these drugs are phenothiazines, butyrophenones, barbiturate and non-barbiturate hypnotics, benzodiazepines, and the Hypno-analgesic, ketamine.\[38\] Midazolam, being a popular benzodiazepine was included in this review. It has sedative, anxiolytic, anticonvulsant properties, and also causes anterograde amnesia. The major advantage it provides is of inducing a safe and effective moderate sedation stage without risk of any cardiopulmonary complications. As compared to other benzodiazepines, midazolam does not produce prolonged sedation.\[39\] Among the various routes for administration of midazolam, Musani IE et al. (2015)\[19\] observed that nasal route was more preferred as compared to oral route in terms of onset and recovery, whereas Kunusoth R et al. (2019)\[31\] reported that there was no statistically significant difference when comparing nasal route to intravenous route. However, other routes such as aerosol, sublingual routes were reported to have better acceptance and behavior management compared to the intranasal route.\[18,23\] Although all of these routes can induce an anxiolysis state but only intravenous route can induce deep sedation stage.\[32\] The reason for the lesser preference of the oral route can be contributed to its inability to titrate reliably. Also, if an additional dose is required, because of variability in absorption and onset of action the procedure is considered to be of high risk.\[40,41\] Malhotra PU (2016),\[24\] Surender MN (2014)\[15\] preferred combination of ketamine and midazolam as compared to dexmedetomidine in terms of behavior management and duration for the onset of sedation respectively. Chayapathi V (2018)\[30\] reported propofol to be better than ketamine and midazolam combination in terms of sedation depth. The major advantage combination of midazolam and ketamine provides is that a lesser dosage is required for the sedative effect to occur.\[42,43\] The combination provides to overcome the issues presented by ketamine as sedative and midazolam as an anxiolytic agent. Lokken (1994),\[42\] Roelofse JA (1998),\[43\] and Moreira TA (2013)\[44\] in their studies have shown that a combination of midazolam and ketamine is better as compared to midazolam and ketamine individually.

In terms of cost-effectiveness, inhalation (nitrous oxide) costs around $25 to $100 (1,779–7,117 INR), light oral sedation is estimated to be around $150 to $500 (10,676–35,588 INR), depending upon the drug and i/v sedation is estimated around $250 to $900 (17,794–64,059 INR). However, the cost for GA procedure in the dental setting is higher around $7,303 (5,20,612 INR), as the procedure is to be conducted in the hospital setting.\[45\]

When comparing the drug of choice for procedures involving minors (less than 16 years) and adults (more than 16 years); Midazolam alone was observed to the preferred drug in procedures involving minors in the dental setting.\[14,18,23\] However, Stephen MC et al. (2015) preferred chloral hydrate for use in minors for auditory brainstem response testing procedure.\[28\] This finding
was in accordance to National Clinical Guideline Centre (UK), 2010 where midazolam was considered to the drug of choice for children undergoing dental procedures and in endoscopy procedure in children, it recommended intravenous midazolam (for upper endoscopy) and fentanyl in combination with intravenous midazolam for lower endoscopy procedures. For children who have to undergo remove the, painful procedures (laceration or orthopaedic treatment) nitrous oxide (in oxygen) and/or midazolam (oral or intranasal) is recommended.

The reason for the widespread popularity of midazolam can be contributed to the minimum side effects midazolam sedation is associated with. Although, oral midazolam preparation has a bitter taste but it can be easily disguised by giving/ mixing it with apple juice or flavored juices. In contrast to the National Clinical Guideline Centre (UK), Brown TB (2005) preferred Ketamine followed by Etomidate, fentanyl, and midazolam for usage in children. The main reason for the preference of ketamine is its faster onset, analgesic and sedative effects, minimal respiratory depression, and adequate operating time. However, the major side effect of ketamine offers is vomiting. In the present review in the case of adults for dentistry and medical procedures various agents, either used alone or in combination were identified. For dental procedures, dexmedetomidine and propofol were considered better as compared to midazolam, Midazolam and ketamine combination. Similarly, for medical procedures, dexmedetomodine, propofol, midazolam and fentanyl, and fentanyl and propofol combination were preferred sedative agents. Reason can be the advantage dexmedetomidine offers by producing milder analgesia without respiratory depression and sedation characterized by quick and easy arousal and lesser cognitive impairment. The advantages propofol provides is of rapid onset and recovery, with clear headedness compared to other agents along with having an antiemetic and antipruritic properties, making it well suited ambulatory conscious sedative agent. Also propofol can be administered as a target-controlled infusion (TCI) which can effectively be used to provide conscious sedation for dentistry. In a study by Samir PV (2017) wherein he compared the effectiveness of slow and rapid infusion of nitrous oxide and reported faster achievement of sedation in rapid infusion group and no statistical difference in the incidence of hypoxia in between the groups (P value <0.512). However, in a study by Stokes and Huston, they have demonstrated a lower incidence of apnea in patients who received slow induction as compared to rapid induction of sedative agent.

The advantages conscious sedation provides over general anesthesia as a method for pharmacological behavior management makes it an easier and faster choice for use in short duration procedures, both in medical and dental setup. Based on the present results, midazolam can be crowned as the most preferred drug for conscious sedation involving children and adults. The use of sedation is surely becoming an indispensable part of a medical and dental fraternity in India. However, the number of trials present in the literature is limited and is not evenly distributed within Indian boundaries. The concentration of trials within some states does identify the need for other states to participate in these trials.

**Limitation of Present Review**

The present narrative review explores the literature related to both medical and dental fraternities exploring the trends in sedation practice. The major limitation is that the present review focuses on the published literature and may not highlight the true concerns of real practice (related to availability, cost-effectiveness). The present review was conducted as a narrative review. Hence, it focused on not a single research question but described an overview of the sedative usage in India. To answer various questions related to like complications (such as sedation, hypotension, and bradycardia) and preference of one drug over other, further surveys and systematic reviews are required.

**Conclusion**

The choice of the sedative agent may vary according to social, economic, population group ethnicity, and even availability of conscious sedation facility. According to our review, midazolam appears to fulfil most of these criteria in a developing country like India. In summary, midazolam remains the drug of choice in both medical and dental worlds due to its various advantages. However other drug benefits can’t be side-lined but to prove their dominance further trials are required.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Guidelines for Use of Sedation and General Anesthesia by Dentists [Internet]. American Dental Association 2016 [cited 2020 Jan 25]. Available from: https://www.ada.org/~/media/ADA/Education%20and%20Careers/Files/ADA_Sedation_Use_Guidelines.pdf?la=en.
2. Historical Development of Conscious Sedation [online]. Pocket Dentistry; 2015 [cited 2019 Jan 20]. Available at: https://pocketdentistry.com/1-historical-development-of-conscious-sedation/.
3. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Trichloroethylene, Tetrachloroethylene, and Some Other Chlorinated Agents. Lyon (FR): International Agency for Research on Cancer; 2014. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 106.) CHLORAL AND CHLORAL HYDRATE. Available from: https://www.ncbi.nlm.nih.gov/books/NBK294283/

4. Woolley SM, Hingston EJ, Shah J, Chadwick BL. Paediatric conscious sedation: Views and experience of specialists in paediatric dentistry. Br Dent J 2009;207:E11; discussion 280–1.

5. Klompas M, Li L, Szumita P, Kleinman K, Murphy MV; CDC Prevention Epicenters Program. Associations between different sedatives and ventilator-associated events, length-of-stay, and mortality in mechanically ventilated patients. Chest 2016;149:1373-9.

6. Gertler R, Brown HC, Mitchell DH, Silivus EN. Dexametomidine: A novel sedative-anaesthetic agent. Proc (Bayl Univ Med Cent) 2001;14:13-21.

7. Ahmad M, Patel JN, Vipparthy SC, Divecha C, Barzallo PX, Kim M, et al. Conscious sedation versus general anesthesia in transcatheter aortic valve replacement: A cost and outcome analysis. Cureus 2019;11:e4812.

8. Practice guidelines for moderate procedural sedation and analgesia 2018: A report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology. American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology*. Anesthesiology 2018;128:437-79.

9. Corcuera-Flores JR, Silvestre-Rangil J, Cutando-Soriano A, López-Jiménez J. Current methods of sedation in dental patients-A systematic review of the literature. Med Oral Patol Oral Cir Bucal 2016;21:e579-86.

10. Anesthesiology recognized as a dental specialty. American Dental Association 2019 [cited 2020 Jan 25]. Available from: https://www.ada.org/en/publications/ada-news/2019-archive/march/anesthesiology-recognized-as-a-dental-specialty.

11. Arksey H, O'Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol 2005;8:19–32.

12. Levac D, Colquhoun H, O'Brien KK. Scoping studies: Advancing the methodology. Implement Sci 2010;5:69.

13. Dhuvad JM, Kshisagar RA, Dhuvad MM. Comparative evaluation of vital parameters during third molar surgery under local anaesthesia with and without sedative agents. J Clin Diag Res 2014;8:ZC57-60.

14. Mitra S, Kazal S, Anand LK. Intranasal clonidine vs. midazolam as premedication in children: A randomized controlled trial. Indian Pediatr 2014;51:113-8.

15. Surendar MN, Pandey RK, Sakensen AK, Kumar R, Chandra G. A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: A triple blind randomized study. J Clin Pediatr Dent 2014;38:255-61.

16. Keerthy PH, Balakrishna R, Srungeri KM, Singhvi N, John J, Islam M. Comparative evaluation of propofol and midazolam as conscious sedatives in minor oral surgery. J Maxillofac Oral Surg 2015;14:773-83.

17. Takkar D, Rao A, Sheny R, Rao A, Suprabha BS. Evaluation of nitrous oxide inhalation sedation during inferior alveolar block administration in children aged 7-10 years: A randomized control trial. J Indian Soc Pedod Prev Dent 2015;33:239-44.

18. Chopra R, Marwaha M. Assessment of buccal aerosolized midazolam for pediatric conscious sedation. J Investig Clin Dent 2015;6:40-4.

19. Musani IE, Chandan NV. A comparison of the sedative effect of oral versus nasal midazolam combined with nitrous oxide in uncooperative children. Eur Arch Paediatr Dent 2015;16:417-24.

20. Stephen MC, Mathew J, Varghese AM, Kurien M, Mathew GA. A randomized controlled trial comparing intranasal midazolam and chloral hydrate for procedural sedation in children. Otolaryngology Head Neck Surg 2015;153:1042-50.

21. Thota RS, Ambaredekar M, Likhate P. Conscious sedation for middle ear surgeries: A comparison between fentanyl-propofol and fentanyl-midazolam infusion. Saudi J Anaesth 2015;9:117-21.

22. Done V, Kotha R, Vasa AA, Sahana S, Jadadoddi RK, Bezawada S. A comparison of the effectiveness of oral midazolam - N2O versus oral ketamine - N2O in pediatric patients-An in vivo study. J Clin Diag Res 2016;10:ZC45-8.

23. Shamugasenan AV, Asokan S, John J, Priya PR, Raaja MT. Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatr Dent 2016;38:106-11.

24. Malhotra PU, Thakur S, Singhal P, Chauhan D, Jayam C, Sood R, et al. Comparative evaluation of dexmedetomidine and midazolam-ketamine combination as sedative agents in pediatric dentistry: A double-blinded randomized controlled trial. Contemp Clin Dent 2016;7:186-92.

25. Bishnoi V, Kumar B, Bhagat H, Salunke P, Bishnoi S. Comparison of dexmedetomidine versus midazolam-fentanyl combination for monitored anesthesia care during burr-hole surgery for chronic subdural hematoma. J Neurosurg Anesthesiol 2016;28:141-6.

26. Ramaswamy SS, Parmala B. Comparative evaluation of two different loading doses of dexmedetomidine with midazolam-fentanyl for sedation in vitreoretinal surgery under peribulbar anaesthesia. Indian J Anaesth 2016;60:89-93.

27. Subramaniam P, Babu KG, Lakhota D. Evaluation of nitrous oxide-oxygen and triclofos sodium as conscious sedative agents. J Indian Soc Pedod Pedev Dent 2017;35:156-161.

28. Samir PV, Namineni S, Sarada P. Assessment of hypoxia, sedation level, and adverse events occurring during inhalation sedation using preadjusted mix of 30% nitrous oxide +70% oxygen. J Indian Soc Pedod Pedev Dent 2017;35:338-45.

29. Prabhudev AM, Chogtu B, Magazine R. Comparison of midazolam with fentanyl-midazolam combination during flexible bronchoscopy: A randomized, double-blind, placebo-controlled study. Indian J Pharmacol 2017;49:304-11.

30. Chhayapatthi V, Kalra M, Bakshi AS, Mahajan A. A comparison of ketamine+midazolam to propofol for procedural sedation for lumbar puncture in pediatric oncology by nonanesthesiologists—A randomized comparative trial. Pediatr Blood Cancer 2018;65:e27108.

31. Kunusoth R, Tej G, Ealla KK, Kathuroju PK, Ayyagari A, Alwala AM. Comparative analysis of intravenous midazolam with nasal spray for conscious sedation in minor oral and maxillofacial surgeries. J Pharm Bioallied Sci 2019;11:S42-50.

32. Sivasubramani SM, Pandyan DA, Chinnasamy R, Kuppusamy SK. Comparison of bite force after administration of midazolam and dexmedetomidine for conscious sedation in minor oral surgery. J Pharm Bioallied Sci 2019;11:S446-9.

33. Lee C, Casserly I, Fahy E. Comparing outcomes in patients undergoing TAVI: General anaesthetic versus conscious sedation. Heart 2017;103:A25-6.

34. Pedlar J. Control of pain and anxiety: Selection of and preparation for sedation or anaesthesia. In: Pedlar J, W . Frame J, editors. Pocket Dentistry [Internet]. 2nd ed. Elsevier Limited; 2007 [cited 2019 Dec 31]. p. 12-23. Available from: https://www.sciencedirect.com/book/9780443100734/oral-and-maxillofacial-surgery.

35. Southerland JH, Brown LR. Conscious intravenous sedation in dentistry: A review of current therapy. Dent Clin North Am
Joshi, et al.: Conscious sedation: Where does India stand?

2016;60:309-46.

36. Kapur A, Kapur V. Conscious sedation in dentistry. Ann Maxillofac Surg 2018;8:320-3.

37. McDonald R, Avery D, Dean J. Dentistry for the Child and Adolescent. 9th ed. St. Louis, Mo: Mosby; 2011.

38. Lauven PM. Pharmacology of drugs for conscious sedation. Scand J Gastroenterol Suppl 1990;179:1-6.

39. Damle SG, Gandhi M, Laheri V. Comparison of oral ketamine and oral midazolam as sedative agents in pediatric dentistry. J Indian Soc Pedod Prev Dent 2008;26:97-101.

40. Tyagi P, Dixit U, Tyagi S, Jain A. Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. J Clin Pediatr Dent 2012;36:383-8.

41. Hass DA. Practice enhancement and knowledge PEAK [Internet]. Oral sedation in dental practice 2015 [cited 2020 Jan 28]. Available from: https://www.globalbeautyllc.com/wp-content/uploads/2016/09/oral-sedation.pdf.

42. Lokken P, Bakstad OJ, Fonnelop E, Skogedal N, Hellsten K, Bjerkelund CE, et al. Conscious sedation by rectal administration of midazolam or midazolam plus ketamine as alternatives to general anesthesia for dental treatment of uncooperative children. Scand J Dent Res 1994;102:274-80.

43. Roelofse JA, Louw LR, Roelofse PG. A double blind randomized comparison of oral trimeprazine-methadone and ketamine-midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesth Prog 1998;45:3-11.

44. Moreira TA, Costa PS, Costa LR, Jesus Franca CR, Antunes DE, Gomes HS, et al. Combined oral midazolam–ketamine better than midazolam alone for sedation of young children: A randomized controlled trial. Int J Paediatr Dent 2013;23:207-15.

45. Rashewsky S, Parameswaran A, Sloane C, Ferguson F, Epstein R. Time and cost analysis: Pediatric dental rehabilitation with general anesthesia in the office and the hospital settings. Anesth Prog 2012;59:147-53.

46. National Clinical Guideline Centre (UK). Sedation in Children and Young People: Sedation for Diagnostic and Therapeutic Procedures in Children and Young People [Internet]. London: Royal College of Physicians (UK); 2010 Dec. (NICE Clinical Guidelines, No. 112.).

47. Isik B, Baygin Ö, Bodur H. Effect of drinks that are added as flavoring in oral midazolam premedication on sedation success. Pediatr Anesth 2008;18:494-500.

48. Brown TB, Lovato LM, Parker DI. Procedural sedation in the acute care setting. Am Fam Physician 2005;71:85-90.

49. Darlong V, Shende D, Subramanyam MS, Sunder R, Naik A. Oral ketamine or midazolam or low dose combination for premedication in children. Anaesth Intensive Care 2004;32:246-9.

50. Aydogan MS, Parlakpinar H, Ali Erdogan M, Yucel A, Ucar M, Sağır M, et al. Effects of dexmedetomidine and midazolam on motor coordination and analgesia: A comparative analysis. Curr Ther Res Clin Exp 2013;75:22-6.

51. Calvey TN, Williams NE, editors. Principles and Practice of Pharmacology for Anaesthetist. 5th ed. Massachusetts: Blackwell Publishing; 2008. Intravenous anaesthetic agents; p. 110–28.

52. Blayney MR, Ryan JD, Malins AF. Propofol target-controlled infusions for sedation—A safe technique for the non-anaesthetist? Br Dent J 2003;194:450-2.

53. Stokes DN, Hutton P. Rate dependent induction phenomena with propofol: Implications for the relative potency of intravenous anaesthetics. Anaesth Analg 1991;72:578-83.